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Introduction: Nowdays, great effort is put into development of 
effective in vitro model for prediction of blood brain barrier (BBB) 
penetration of drugs. Recent investigation showed that gliclazide 
has protective effect on the brain of diabetic rat, but it has low BBB 
permeability that could be increased.
Aim: The aim of this study was to investigate whether in vitro models 
of gliclazide distribution in systems n-octanol/water and cyclohexane/
water are good in vitro models for the prediction of its penetration 
as well as for the prediction of influence of dexycholic acid (DCA) 
influence on penetration.
Patients (or Materials) and Methods: Distribution coefficient (logD) 
was determined using a …Flask shake “method. Partition profile was 
determined over physiological pH range (from pH 1.2 HCl solution, 
pH 4.5 acetate buffer, pH 6.8 and 7.4 phosphate buffer, and pH 7 
distilled water) for 5 combinations of n-octanol or cyclohexane with 
aquase gliclazide solution (10 µg/mL) of different pH and with or 
without the addition of DCA (0.5 mM) into n-octanol or cyclohexane 
phase. The analyses were done in triplicate for each pair of organic 
solvent/ water. Concentrations of gliclazide were determined using 
high-performance liquid chromatography. Values of logD at pH 7.4 
were compared with literature date of gliclazide BBB penetration and 
influence of DCA on it penetration.
Results: Higher partition into organic layer was found in system 
n-octanol/water than cyclohexane/water. Also DCA increased partition 
of gliclazide in system cyclohexane/water but not in system n-octanol/
water. Value of logD at pH 7.4 without DCA in organic layer in sys-
tem n-octanol/water was 0.34 (0.05) and in system cyclohexane/water 
was –0.74 (0.11). Value of logD at pH 7.4 with DCA in organic layer 
in system n-octanol/water was 0.54 (0.07) and in system cyclohex-
ane/water was 0.18 (0.01). Thus, partition of gliclazide in system 
cyclohexane/water better correlate with in vivo data where penetration 
of gliclazide was increased with DCA pretreatement, but in diabetic 
animals, penetration was increased in group with and without DCA 
pretreatment what this in vitro system could not predict.
Conclusion: Investigated system cyclohexane/water predicted poor 
gliclazide BBB penetration and the influence of DA on gliclazide pen-
etration but system n-octanol/water failed to do so. However, more 
substances are need to claim that system cyclohexane/water success-
fully could predict drugs BBB penetration.
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Introduction: Azathioprine (AZA) is an immunosuppressive drug 
widely used in inflammatory bowel disease (IBD). Few data on 
azathioprine (AZA) therapy IBD exist for children. We evaluated 
whether the 6-thioguanine nucleotides (6-TGN) level predicts AZA 
refractoriness in children with IBD and whether children benefit an 
AZA dose escalation.
Patients (or Materials) and Methods: Seventy-eight children with 
IBD initially treated with an AZA dose of 1.5 to 2.5 mg/kg/d were ret-
rospectively included. The dose was adjusted based on the clinical sta-
tus. 6-TGN and Me6-MPN thiopurine metabolites were determined 
by HPLC. The receiver operating characteristic curve and logistic 
regression were used to determine predictors for AZA resistance.
Results: Initially, 18 of 40 (45%) patients receiving a dose below 2 
mg/kg/d and 11 of 38 (28.9%) patients receiving a dose of 2 to 2.5 
mg/kg/d achieved remission. The 6-TGN level above 250 pmol/8.108 
RBCs was associated with a higher remission rate, although non-
significant. Among 35 patients with a dose escalation due to treat-
ment failure, 12 (34.3%) achieved remission (the median 6-TGN 
level increased from 260 to 394 pmol/8.108 RBCs (P = 0.002)), 23 
(67.6%) were AZA refractory. A 6-TGN level above 405 pmol/8.108 
RBCs was the only predictor for AZA resistance (sensitivity, 78.3%; 
specificity, 75%; OR, 10.8 [95% CI, 2.1–55.7], P = 0.004)).
Conclusion: Drug monitoring of thiopurine metabolites is useful to 
identify children with IBD resistant to AZA. Children who cannot 
achieve remission despite a 6-TGN level above 405 pmol/8.108 RBCs 
should receive alternative therapies.
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Introduction: Antibacterial drugs are among the most common med-
ications used by pregnant women. Although the medical literature 
generally defines nitrofurantoin as safe antibiotic during the first tri-
mester of pregnancy, lately new concerns of association between birth 
defects after exposure to nitrofurantoin during the first trimester of 
pregnancy have surfaced. We conducted a large population-based ret-
rospective cohort study to assess the association between exposure to 
nitrofurantoin during the first trimester of pregnancy (including cases 
of medical terminations of pregnancy or stillbirth) and birth defects.
Patients (or Materials) and Methods: A computerized database of 
medications dispensed from 1999 to 2009 to all women registered 
in the “Clalit” HMO, in the southern district of Israel, was linked 
with 2 computerized databases containing maternal and infant hos-
pitalization records. Associations between exposure to nitrofurantoin 
during the first trimester and birth defects were assessed. The follow-
ing confounders were controlled for: parity, maternal age, ethnicity, 
maternal pregestational diabetes, year of birth or medical pregnancy 
termination, and smoking.
Results: A total of 105,492 pregnancies were included in our 
research, of which 1112 pregnancies were pregnancy terminations 
because of medical reasons. A total of 1329 infants and abortuses 
